ACADIA (NASDAQ: ACAD) officer sells 1,942 shares after RSU vesting

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS’ principal accounting officer, James Kihara, reported routine equity compensation activity and related share sales. He exercised or converted a total of 3,769 restricted stock units into common stock at a conversion price of $0.0000 per share, each unit representing one share of common stock.

Across March 24–26, 2026, he disposed of 1,942 shares of common stock in transactions coded as open‑market sales at prices between $21.47 and $21.7253 per share. A footnote explains these mandatory sales were made to cover withholding taxes and related tax items in connection with vesting of restricted stock units and were intended to meet Rule 10b5‑1(c) requirements. After these transactions, Kihara directly holds 26,885 shares of common stock and 4,883 restricted stock units that vest annually in four equal installments starting on March 24, 2026 and March 25, 2025.

Insider Trade Summary

Net Seller: 1,942 shares ($41,895)

Net Sell 7 txns

Insider Kihara James

Role PRINCIPAL ACCOUNTING OFFICER

Sold 1,942 shs ($42K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,097	$21.65	$24K
Sale	Common Stock	12	$21.7253	$260.70
Exercise	Restricted Stock Units	2,142	$0.00	--
Sale	Common Stock	833	$21.47	$18K
Exercise	Common Stock	2,142	$0.00	--
Exercise	Restricted Stock Units	1,627	$0.00	--
Exercise	Common Stock	1,627	$0.00	--

Holdings After Transaction: Common Stock — 26,897 shares (Direct); Restricted Stock Units — 4,284 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The restricted stock units vest in four equal annual installments beginning March 24, 2026. The restricted stock units vest in four equal annual installments beginning March 25, 2025.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kihara James

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRINCIPAL ACCOUNTING OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/24/2026		M		1,627	A	(1)	26,685	D
Common Stock	03/25/2026		S(2)		833	D	$21.47	25,852	D
Common Stock	03/25/2026		M		2,142	A	(1)	27,994	D
Common Stock	03/26/2026		S(2)		1,097	D	$21.65	26,897	D
Common Stock	03/26/2026		S(2)		12	D	$21.7253	26,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/24/2026		M			1,627	(3)	(3)	Common Stock	1,627	$0	4,883	D
Restricted Stock Units	(1)	03/25/2026		M			2,142	(4)	(4)	Common Stock	2,142	$0	4,284	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).

3. The restricted stock units vest in four equal annual installments beginning March 24, 2026.

4. The restricted stock units vest in four equal annual installments beginning March 25, 2025.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	03/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ACAD (ACADIA PHARMACEUTICALS) report for James Kihara?

ACAD reported that principal accounting officer James Kihara exercised or converted 3,769 restricted stock units into common stock and sold 1,942 common shares. The transactions occurred between March 24 and March 26, 2026, at prices around $21.50 per share.

Were the ACAD insider share sales by James Kihara discretionary or tax-related?

The reported share sales were tax-related. A footnote states the mandatory sales were executed to cover withholding taxes and related items from restricted stock unit vesting and were intended to comply with Rule 10b5-1(c) under the Exchange Act.

How many ACAD shares did James Kihara sell and at what prices?

James Kihara sold a total of 1,942 ACAD common shares. The reported sale prices ranged from $21.47 to approximately $21.7253 per share, based on separate transactions on March 25 and March 26, 2026.

How many ACADIA PHARMACEUTICALS shares does James Kihara hold after these transactions?

Following the reported transactions, James Kihara directly holds 26,885 shares of ACAD common stock. He also holds 4,883 restricted stock units, each representing a contingent right to receive one additional share of the company’s common stock.

What do the ACAD restricted stock units reported for James Kihara represent?

Each restricted stock unit reported for ACAD’s James Kihara represents a contingent right to receive one share of ACAD common stock. The units vest in four equal annual installments beginning on March 24, 2026, and March 25, 2025, according to the disclosed schedules.

How do the vesting schedules work for James Kihara’s ACAD restricted stock units?

The filing explains that some restricted stock units vest in four equal annual installments beginning March 24, 2026, while another grant vests in four equal annual installments beginning March 25, 2025. Each vested unit converts into one share of ACAD common stock.